CVS Health (NYSE:CVS - Get Free Report) had its price objective increased by stock analysts at Truist Financial from $76.00 to $82.00 in a report released on Friday,Benzinga reports. The brokerage currently has a "buy" rating on the pharmacy operator's stock. Truist Financial's target price suggests a potential upside of 19.13% from the stock's previous close.
Several other equities research analysts also recently issued reports on the stock. Wells Fargo & Company raised their target price on shares of CVS Health from $68.00 to $73.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. UBS Group reduced their target price on CVS Health from $62.00 to $59.00 and set a "neutral" rating for the company in a research note on Tuesday, February 11th. Mizuho increased their price target on CVS Health from $70.00 to $76.00 and gave the company an "outperform" rating in a research note on Wednesday, April 9th. JPMorgan Chase & Co. lifted their price objective on shares of CVS Health from $80.00 to $81.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 18th. Finally, Cantor Fitzgerald upgraded shares of CVS Health from a "neutral" rating to an "overweight" rating in a research note on Wednesday, February 12th. Four analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $71.83.
Get Our Latest Stock Analysis on CVS
CVS Health Stock Down 0.1 %
Shares of NYSE:CVS traded down $0.09 during midday trading on Friday, reaching $68.83. The company had a trading volume of 4,384,812 shares, compared to its average volume of 11,754,556. The business's 50 day moving average price is $65.67 and its 200 day moving average price is $58.63. CVS Health has a 1-year low of $43.56 and a 1-year high of $71.66. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. The stock has a market cap of $86.78 billion, a PE ratio of 18.81, a P/E/G ratio of 0.98 and a beta of 0.57.
CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. Research analysts forecast that CVS Health will post 5.89 EPS for the current fiscal year.
Insider Activity
In related news, Director Michael F. Mahoney purchased 30,000 shares of CVS Health stock in a transaction dated Tuesday, February 18th. The shares were bought at an average cost of $66.70 per share, for a total transaction of $2,001,000.00. Following the purchase, the director now owns 39,356 shares in the company, valued at approximately $2,625,045.20. This trade represents a 320.65 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP James David Clark sold 7,513 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total transaction of $498,487.55. Following the transaction, the senior vice president now owns 8,394 shares of the company's stock, valued at approximately $556,941.90. This represents a 47.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.24% of the company's stock.
Institutional Trading of CVS Health
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Ridgewood Investments LLC increased its stake in shares of CVS Health by 255.7% in the fourth quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator's stock valued at $28,000 after buying an additional 450 shares during the period. Stonebridge Financial Group LLC acquired a new position in CVS Health in the 4th quarter valued at approximately $28,000. Hopwood Financial Services Inc. acquired a new position in shares of CVS Health during the fourth quarter worth $29,000. McIlrath & Eck LLC grew its stake in shares of CVS Health by 32.6% in the fourth quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator's stock worth $32,000 after purchasing an additional 174 shares during the last quarter. Finally, MV Capital Management Inc. increased its holdings in CVS Health by 63.9% in the first quarter. MV Capital Management Inc. now owns 741 shares of the pharmacy operator's stock valued at $50,000 after purchasing an additional 289 shares during the period. Institutional investors own 80.66% of the company's stock.
About CVS Health
(
Get Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Featured Articles
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
